A Phase I Study of RG3638 as a Single Agent in Patients with Solid Tumors, and RG3638 in Combination with Erlotinib in Patients with Met diagnostic-positive Non-Small Cell Lung Cancer

Trial Profile

A Phase I Study of RG3638 as a Single Agent in Patients with Solid Tumors, and RG3638 in Combination with Erlotinib in Patients with Met diagnostic-positive Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2016

At a glance

  • Drugs Onartuzumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 06 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top